(RPRX) Royalty Pharma - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: GB00BMVP7Y09
Stock:
Total Rating 47
Risk 82
Buy Signal 0.03
| Risk 5d forecast | |
|---|---|
| Volatility | 23.2% |
| Relative Tail Risk | -3.86% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.47 |
| Alpha | 35.32 |
| Character TTM | |
|---|---|
| Beta | 0.182 |
| Beta Downside | 0.080 |
| Drawdowns 3y | |
|---|---|
| Max DD | 31.67% |
| CAGR/Max DD | 0.39 |
EPS (Earnings per Share)
Revenue
Description: RPRX Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 770.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA -2.51 > 1.0 |
| NWC/Revenue: -0.72% < 20% (prev 24.23%; Δ -24.96% < -1%) |
| CFO/TA 0.13 > 3% & CFO 2.49b > Net Income 770.9m |
| Net Debt (8.33b) to EBITDA (1.63b): 5.10 < 3 |
| Current Ratio: 0.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (559.6m) vs 12m ago -4.99% < -2% |
| Gross Margin: 85.97% > 18% (prev 0.57%; Δ 8541 % > 0.5%) |
| Asset Turnover: 12.57% > 50% (prev 12.42%; Δ 0.15% > 0%) |
| Interest Coverage Ratio: 5.58 > 6 (EBITDA TTM 1.63b / Interest Expense TTM 307.7m) |
Altman Z'' 1.25
| A: -0.00 (Total Current Assets 619.0m - Total Current Liabilities 636.2m) / Total Assets 19.62b |
| B: 0.12 (Retained Earnings 2.36b / Total Assets 19.62b) |
| C: 0.09 (EBIT TTM 1.72b / Avg Total Assets 18.92b) |
| D: 0.24 (Book Value of Equity 2.36b / Total Liabilities 9.91b) |
| Altman-Z'' Score: 1.25 = BB |
Beneish M
| DSRI: 31.20 (Receivables 883.7m/27.0m, Revenue 2.38b/2.26b) |
| GMI: 0.66 (GM 85.97% / 56.65%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 1.05 (Revenue 2.38b / 2.26b) |
| TATA: -0.09 (NI 770.9m - CFO 2.49b) / TA 19.62b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of RPRX shares?
As of February 28, 2026, the stock is trading at USD 46.21 with a total of 4,176,944 shares traded.
Over the past week, the price has changed by +2.42%, over one month by +14.02%, over three months by +16.07% and over the past year by +41.77%.
Over the past week, the price has changed by +2.42%, over one month by +14.02%, over three months by +16.07% and over the past year by +41.77%.
Is RPRX a buy, sell or hold?
Royalty Pharma has received a consensus analysts rating of 4.25.
Therefore, it is recommended to buy RPRX.
- StrongBuy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RPRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 51 | 10.4% |
| Analysts Target Price | 51 | 10.4% |
RPRX Fundamental Data Overview February 24, 2026
P/E Trailing = 25.3483
P/E Forward = 10.5932
P/S = 10.9738
P/B = 2.485
P/EG = 2.7801
Revenue TTM = 2.38b USD
EBIT TTM = 1.72b USD
EBITDA TTM = 1.63b USD
Long Term Debt = 8.57b USD (from longTermDebt, last quarter)
Short Term Debt = 380.0m USD (from shortTermDebt, last quarter)
Debt = 8.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.33b USD (from netDebt column, last quarter)
Enterprise Value = 34.41b USD (26.10b + Debt 8.95b - CCE 637.5m)
Interest Coverage Ratio = 5.58 (Ebit TTM 1.72b / Interest Expense TTM 307.7m)
EV/FCF = 13.82x (Enterprise Value 34.41b / FCF TTM 2.49b)
FCF Yield = 7.24% (FCF TTM 2.49b / Enterprise Value 34.41b)
FCF Margin = 104.7% (FCF TTM 2.49b / Revenue TTM 2.38b)
Net Margin = 32.42% (Net Income TTM 770.9m / Revenue TTM 2.38b)
Gross Margin = 85.97% ((Revenue TTM 2.38b - Cost of Revenue TTM 333.6m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.75 (Enterprise Value 34.41b / Total Assets 19.62b)
Interest Expense / Debt = 1.05% (Interest Expense 94.2m / Debt 8.95b)
Taxrate = 39.90% (142.0m / 355.9m)
NOPAT = 1.03b (EBIT 1.72b * (1 - 39.90%))
Current Ratio = 0.97 (Total Current Assets 619.0m / Total Current Liabilities 636.2m)
Debt / Equity = 1.38 (Debt 8.95b / totalStockholderEquity, last quarter 6.48b)
Debt / EBITDA = 5.10 (Net Debt 8.33b / EBITDA 1.63b)
Debt / FCF = 3.35 (Net Debt 8.33b / FCF TTM 2.49b)
Total Stockholder Equity = 6.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.07% (Net Income 770.9m / Total Assets 19.62b)
RoE = 11.89% (Net Income TTM 770.9m / Total Stockholder Equity 6.48b)
RoCE = 11.41% (EBIT 1.72b / Capital Employed (Equity 6.48b + L.T.Debt 8.57b))
RoIC = 6.95% (NOPAT 1.03b / Invested Capital 14.86b)
WACC = 5.07% (E(26.10b)/V(35.05b) * Re(6.59%) + D(8.95b)/V(35.05b) * Rd(1.05%) * (1-Tc(0.40)))
Discount Rate = 6.59% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 11.94%
[DCF] Terminal Value 86.28% ; FCFF base≈2.60b ; Y1≈2.59b ; Y5≈2.71b
[DCF] Fair Price = 169.3 (EV 80.86b - Net Debt 8.33b = Equity 72.53b / Shares 428.4m; r=5.90% [WACC]; 5y FCF grow -1.23% → 2.90% )
EPS Correlation: -16.36 | EPS CAGR: -11.47% | SUE: -4.0 | # QB: 0
Revenue Correlation: 27.84 | Revenue CAGR: 2.74% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.23 | Chg7d=+0.079 | Chg30d=+0.079 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-12-31): EPS=5.03 | Chg7d=-0.047 | Chg30d=-0.019 | Revisions Net=+1 | Growth EPS=+4.1% | Growth Revenue=+4.7%
EPS next Year (2027-12-31): EPS=5.44 | Chg7d=-0.177 | Chg30d=-0.197 | Revisions Net=-3 | Growth EPS=+8.1% | Growth Revenue=+6.3%
[Analyst] Revisions Ratio: +0.20 (3 Up / 2 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.0% (Discount Rate 7.9% - Earnings Yield 3.9%)
[Growth] Growth Spread = +7.4% (Analyst 11.4% - Implied 4.0%)
P/E Forward = 10.5932
P/S = 10.9738
P/B = 2.485
P/EG = 2.7801
Revenue TTM = 2.38b USD
EBIT TTM = 1.72b USD
EBITDA TTM = 1.63b USD
Long Term Debt = 8.57b USD (from longTermDebt, last quarter)
Short Term Debt = 380.0m USD (from shortTermDebt, last quarter)
Debt = 8.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.33b USD (from netDebt column, last quarter)
Enterprise Value = 34.41b USD (26.10b + Debt 8.95b - CCE 637.5m)
Interest Coverage Ratio = 5.58 (Ebit TTM 1.72b / Interest Expense TTM 307.7m)
EV/FCF = 13.82x (Enterprise Value 34.41b / FCF TTM 2.49b)
FCF Yield = 7.24% (FCF TTM 2.49b / Enterprise Value 34.41b)
FCF Margin = 104.7% (FCF TTM 2.49b / Revenue TTM 2.38b)
Net Margin = 32.42% (Net Income TTM 770.9m / Revenue TTM 2.38b)
Gross Margin = 85.97% ((Revenue TTM 2.38b - Cost of Revenue TTM 333.6m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.75 (Enterprise Value 34.41b / Total Assets 19.62b)
Interest Expense / Debt = 1.05% (Interest Expense 94.2m / Debt 8.95b)
Taxrate = 39.90% (142.0m / 355.9m)
NOPAT = 1.03b (EBIT 1.72b * (1 - 39.90%))
Current Ratio = 0.97 (Total Current Assets 619.0m / Total Current Liabilities 636.2m)
Debt / Equity = 1.38 (Debt 8.95b / totalStockholderEquity, last quarter 6.48b)
Debt / EBITDA = 5.10 (Net Debt 8.33b / EBITDA 1.63b)
Debt / FCF = 3.35 (Net Debt 8.33b / FCF TTM 2.49b)
Total Stockholder Equity = 6.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.07% (Net Income 770.9m / Total Assets 19.62b)
RoE = 11.89% (Net Income TTM 770.9m / Total Stockholder Equity 6.48b)
RoCE = 11.41% (EBIT 1.72b / Capital Employed (Equity 6.48b + L.T.Debt 8.57b))
RoIC = 6.95% (NOPAT 1.03b / Invested Capital 14.86b)
WACC = 5.07% (E(26.10b)/V(35.05b) * Re(6.59%) + D(8.95b)/V(35.05b) * Rd(1.05%) * (1-Tc(0.40)))
Discount Rate = 6.59% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 11.94%
[DCF] Terminal Value 86.28% ; FCFF base≈2.60b ; Y1≈2.59b ; Y5≈2.71b
[DCF] Fair Price = 169.3 (EV 80.86b - Net Debt 8.33b = Equity 72.53b / Shares 428.4m; r=5.90% [WACC]; 5y FCF grow -1.23% → 2.90% )
EPS Correlation: -16.36 | EPS CAGR: -11.47% | SUE: -4.0 | # QB: 0
Revenue Correlation: 27.84 | Revenue CAGR: 2.74% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.23 | Chg7d=+0.079 | Chg30d=+0.079 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-12-31): EPS=5.03 | Chg7d=-0.047 | Chg30d=-0.019 | Revisions Net=+1 | Growth EPS=+4.1% | Growth Revenue=+4.7%
EPS next Year (2027-12-31): EPS=5.44 | Chg7d=-0.177 | Chg30d=-0.197 | Revisions Net=-3 | Growth EPS=+8.1% | Growth Revenue=+6.3%
[Analyst] Revisions Ratio: +0.20 (3 Up / 2 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.0% (Discount Rate 7.9% - Earnings Yield 3.9%)
[Growth] Growth Spread = +7.4% (Analyst 11.4% - Implied 4.0%)